OmniAb Inc reports results for the quarter ended September 30 - Earnings Summary

OmniAB

13/11/2024 15:32

* OmniAb Inc  OABI.OQ  reported a quarterly adjusted loss
of 16
cents​​ per share for the quarter ended September 30, identical
to the same quarter last year.  The mean expectation of
eight analysts for the quarter was for a loss of 14 cents per
share. Wall Street expected results to range from -16 cents
to -12 cents per share.
    * Revenue fell 23.8% to $4.17 million from a year ago;
analysts
expected $8.40 million. 
    * OmniAb Inc's reported EPS for the quarter was a loss of 16
cents​.
    * The company reported a quarterly loss of $16.37 million.
    * OmniAb Inc shares had risen by 6.1% this quarter and
lost 27.2%
so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for OmniAb Inc is
10.00 
This summary was machine generated from LSEG data November 13 at
03:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.14          -0.16          Missed
 Jun. 30 2024      -0.17          -0.13          Beat
 Mar. 31 2024      -0.16          -0.19          Missed
 Dec. 31 2023      -0.15          -0.14          Beat